NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ: AKLI)’s sale to Virtual Therapeutics for $0.4340 per share of common stock in cash. If you are an Akili shareholder, click here to learn more about your rights and options. Encore Wire Corporation (NASDAQ: WIRE)’s sale to Prysmian for $29 ...

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Akili, Inc. (NASDAQ: AKLI), relating to a tender offer from Vital Therapeutics Corporation. Under the terms of the agreement, Vital Therapeutics Corporation will acquire all the outstandi ...

MILWAUKEE, May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutics. Click here to learn how to join the https://www.ademilaw.com/case/akili-inc or call Guri Ademi toll-free at 866- 264-3995. There is no cost or obligation to you. In the transaction, Akili shareholders will receive only $0.4340 per share of common stock in cash. The transaction agreement unreasonably limits co ...

tROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-40558 Akili, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 92-3 ...

Exhibit 99.1 Akili Reports First Quarter 2024 Financial Results and Provides Business Update Company announces full voluntary prepayment of debt and termination of Amended & Restated Loan and Security Agreement with Silicon Valley Bank Following recent restructuring, focusing efforts primarily on supporting existing customers, executing the amended agreement with Shionogi, and evaluating potential strategic alternatives BOSTON, Mass. –May 14, 2024– Akili, Inc. (Nasdaq: AKLI), a leading digital medicine comp ...

Akili (NASDAQ:AKLI) stock is rocketing higher on Tuesday after the digital medicine company provided investors with a positive corporate update. According to this update, Shionogi has canceled and forgiven $5 million in debt that Akili owed it. The company has also agreed to make payments for Akili’s SDT-001. That includes a $10.5 million upfront payment to cancel future royalty payments and milestone payments. To go along with that, Akili is still eligible for up to $4.5 million in payments from Shionogi f ...

Exhibit 99.1 Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update FY 2023 total revenues of $1.7M, a 420% increase over FY 2022 as EndeavorOTC® gained traction in the market following June 2023 product release Reports fourth quarter 2023 total revenues of $749 thousand, representing 7% growth over the third quarter of 2023, and positive gross margins of 66%, representing a 6 percentage point increase over the third quarter of 2023 Akili partner Shionogi releases pos ...

营收情况 - 公司在财报电话会议中提到，上季度营收达到了创纪录的数字[869] 用户数据增长 - 公司表示，用户数据增长了百分之十五[869] 业绩展望 - 公司对未来展望非常乐观，预计下一季度业绩将继续增长[869]

投资策略 - 投资于低价股票是一种独特的机会，可以帮助投资者扩大投资组合，获取潜在高回报的选择[1] - 设定现实的利润目标是卖出股票的关键，这有助于投资者在交易过程中早期定义他们的财务目标，为有利可图地退出头寸提供了基准[2] 市场监测 - 监控市场趋势是投资低价股票的不可或缺的策略，了解全球经济指标、行业特定发展和一般市场情绪，可以帮助投资者预测股票的走势并及时做出决策[10]

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. (Nasdaq: AKLI) announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of Akili’s AKL-T01 (m ...